Hot Pharma & Healthcare Issues

Daiichi Sankyo soon to begin with clinical trials for Duchenne muscular dystrophy drug, DS-5141b in Japan

Company Report

 Japan-based Daiichi Sankyo Company, Limited revealed that the clinical trial for administration of the Duchenne muscular dystrophy (DMD) treatment drug DS-5141b will soon begin in Japan. The drug has been developed in collaboration with the Orphan Disease Treatment Institute Co., Ltd. (ODTI).  

DMD is a well-known disease affecting one in 3,500 new-born male children irrespective of their ethnicity. DMD happens because muscle cells are not able to develop dystrophin. Dystrophin is a cytoplasmic protein, and is an important part of a protein complex connecting cytoskeleton of a muscle fiber to the adjoining extracellular matrix via the cell membrane. The complex is also known as the costamere or the dystrophin-associated protein complex. However, there is not specific therapy available for this type of disease. 

DMD drug induces exon skipping of dystrophin mRNA to enhance incomplete yet functional dystrophin development. This is considered to be an effective treatment for DMD. This drug has an active ingredient called ENA oligonucleotide, which is an altered nucleic acid produced using Daiichi Sankyo, proprietary technology. Additionally, the company expects to receive manufacturing and marketing approval by the end of 2020.

According to Pharmaion, Pharma and Healthcare consultants, Daiichi Sankyo ‘s commitment towards launching a treatment for will contribute to the medical care by providing new treatment options. The absence valid treatment option will contribute to the demand for muscular dystrophy treatment market in Japan. 


Relevant Reports

India Pharmacy Market Opportunities, 2011 - 2021

Pharmaceutical | 22 Aug, 2016News

India is the second most populated country globally, with a total population of 1.3 billion as of 2015. More than 50% of the country’s population is in the age group of <25 years. India accounted for ~20% share in the global

Relevant News